JP2021531268A5 - - Google Patents

Info

Publication number
JP2021531268A5
JP2021531268A5 JP2021500915A JP2021500915A JP2021531268A5 JP 2021531268 A5 JP2021531268 A5 JP 2021531268A5 JP 2021500915 A JP2021500915 A JP 2021500915A JP 2021500915 A JP2021500915 A JP 2021500915A JP 2021531268 A5 JP2021531268 A5 JP 2021531268A5
Authority
JP
Japan
Prior art keywords
domain
polypeptide
monomer
igg1
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531268A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041406 external-priority patent/WO2020014486A1/en
Publication of JP2021531268A publication Critical patent/JP2021531268A/ja
Publication of JP2021531268A5 publication Critical patent/JP2021531268A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500915A 2018-07-11 2019-07-11 改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021531268A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696618P 2018-07-11 2018-07-11
US62/696,618 2018-07-11
PCT/US2019/041406 WO2020014486A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs

Publications (2)

Publication Number Publication Date
JP2021531268A JP2021531268A (ja) 2021-11-18
JP2021531268A5 true JP2021531268A5 (cg-RX-API-DMAC7.html) 2022-07-14

Family

ID=69142016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500915A Withdrawn JP2021531268A (ja) 2018-07-11 2019-07-11 改変されたFc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20220267460A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820519A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021531268A (cg-RX-API-DMAC7.html)
KR (1) KR20210042326A (cg-RX-API-DMAC7.html)
CN (1) CN113164591A (cg-RX-API-DMAC7.html)
AU (1) AU2019302740A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000392A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106212A1 (cg-RX-API-DMAC7.html)
IL (1) IL279998A (cg-RX-API-DMAC7.html)
MX (1) MX2021000287A (cg-RX-API-DMAC7.html)
WO (1) WO2020014486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4426337A1 (en) * 2021-11-05 2024-09-11 Oslo Universitetssykehus HF Iga fc and igg fc tandem protein constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137382A1 (en) * 2007-04-30 2008-11-13 Centocor, Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
SI2185589T1 (sl) * 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20150058236A (ko) * 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs

Similar Documents

Publication Publication Date Title
IL261674A (en) Protein-like binding proteins with a double variable region have a cross-linking region direction
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2019534277A5 (cg-RX-API-DMAC7.html)
Carter Bispecific human IgG by design
JP2022551969A5 (cg-RX-API-DMAC7.html)
JP2018046872A5 (cg-RX-API-DMAC7.html)
FI3392276T3 (fi) Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö
JP2018537966A5 (cg-RX-API-DMAC7.html)
IL299221A (en) Cd3 binding antibodies
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
HRP20211528T1 (hr) Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2022504802A5 (cg-RX-API-DMAC7.html)
JP2020514301A5 (cg-RX-API-DMAC7.html)
JP2018527903A5 (cg-RX-API-DMAC7.html)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2018522541A5 (cg-RX-API-DMAC7.html)
HRP20150444T1 (hr) Trovalentna, bispecifiäśna protutijela
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
JP2024534545A5 (cg-RX-API-DMAC7.html)
HRP20201004T1 (hr) Modificirani polipeptidi za skelete bispecifičnog protutijela
JP2017504578A5 (cg-RX-API-DMAC7.html)
AR120741A1 (es) Anticuerpos anti-ly6g6d y métodos de uso